Anti-Cancer Drugs Flashcards
Hanahan, 2011
Hallmarks of Cancer
Juntilla and Savage, 2013
The contents of the Tumour Microenvironment
Hurley, 2002
Types of Alkylating Agents
Emadi, 2009
Cyclophosphamide-an alkylating agent used in the treatment of breast and testicular cancers
Lind, 2011
Heavy metals cisplatin and carboplatin are all activated intracellularly to form reactive intermediates that form covalent bonds at the N7 residues to form inter and intra DNA crosslinks
Corrie, 2011
Therepeutic index of cytotoxics-Crossover between the dose of a cytotoxic drug and the number of healthy cells killed limits the use of chemotherapy
Blume-Jensen and Hunter, 2001
Tyrosine Kinase Receptors
Nyati, 2006
EGFRs-Epidermal Growth Factor Receptors
Chapman, 2011
Vemurafenib trials show that even with resistance, vemurafenib provides 5.6 months of progression-free survival compared to 1.6 months with standard decarbazine
Jones, 2009
Transtuzumab/Herceptin is used to treat HER (Human epidermal growth receptor) positive cancers such as breast and gastric
Hodi, 2010
Ipilimumab is an anti-CTLA 4 antibody.
Showed that if 2 year survival can be reached then it is likely that 5 years will be reached
Abraham, 2011
Tamoxifen-A selective Oestrogen Receptor Modulator with agonist and antagonist effects depending on the tissue type
5 years of tamoxifen therapy for oestrogen positive breast cancers reduces recurrence by 41% and mortality by 34%`
Sonenblick, 2015
PARP inhibitors are used in BRCA deficient cancers to prevent the repair of single-stranded DNA breaks
Andtbacka, 2015
TVEK-a herpes virus with oncolytic properties. Has shown promise in melanoma patients with multiple tumours
